Triterpenoid Derivatives Modulating Inflammatory Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for inflammatory, neurodegenerative, and autoimmune diseases, such as celastrol, face challenges due to cellular toxicity and undesirable pharmacokinetic characteristics, limiting their effectiveness and safety profiles.
Innovation Solution
Development of structurally modified chemical entities, including compounds of Formula I, which incorporate variations to enhance drug-like properties and reduce toxicity, for the treatment of inflammatory, neurodegenerative, and autoimmune diseases, such as Alzheimer's, Parkinson's, and rheumatoid arthritis, by modulating inflammatory pathways and cellular responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If celastrol or tripterine is used as therapeutic agents, then anti-inflammatory and neuroprotective effects are achieved, but cellular toxicity and undesirable pharmacokinetic characteristics occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of celastrol and tripterine through variations in R1, X, R2, R3, and R4 substituents. These structural parameter changes aim to optimize the balance between therapeutic efficacy and cellular toxicity, creating analogs with improved safety profiles while maintaining anti-inflammatory and neuroprotective effects.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the core quinone-methide scaffold with various substituent groups. These composite chemical entities integrate beneficial pharmacological properties while attempting to eliminate or reduce toxic characteristics associated with the parent compounds.
2Reliability
If celastrol or tripterine is used as therapeutic agents, then anti-inflammatory and neuroprotective effects are achieved, but undesirable pharmacokinetic characteristics occur
Solution Approach 1:
The patent modifies pharmacokinetic parameters through systematic structural variations of the parent compounds. By changing substituents at different positions (R1, X, R2, R3, R4), the invention aims to optimize absorption, distribution, metabolism, and excretion properties, thereby improving the overall pharmacokinetic profile and duration of action.
3Object-affected harmful factors
If structurally modified chemical entities are developed to reduce toxicity, then safety profile is improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions (core quinone-methide scaffold and variable substituent groups). This modular approach allows systematic exploration of structure-activity relationships while maintaining a manageable framework for designing less toxic analogs.
Data Source
AI summary
Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.